[1] RUSSO V, CARBONE A, RAGO A, et al. Direct oral anticoagulants in octogenarians with atrial fibrillation: it is never too late[J]. J Cardiovasc Pharmacol, 2019, 73(4): 207-214. DOI: 10.1097/FJC.0000000000000661. [2] HAYES K N, ZHANG T T, KIM D H, et al. Benefits and harms of standard versus reduced-dose direct oral anticoagulant therapy for older adults with multiple morbidities and atrial fibrillation[J]. J Am Heart Assoc, 2023, 12(21): e029865. DOI: 10.1161/JAHA.122.029865. [3] CHAN Y H, CHAO T F, CHEN S W, et al. Clinical outcomes in elderly atrial fibrillation patients at increased bleeding risk treated with very low dose vs. regular-dose non-vitamin K antagonist oral anticoagulants: a nationwide cohort study[J]. Eur Heart J Cardiovasc Pharmacother, 2023, 9(8): 681-691. DOI: 10.1093/ehjcvp/pvad058. [4] 中华医学会心血管病学分会,中国生物医学工程学会心律分会. 心房颤动诊断和治疗中国指南[J]. 中华心血管病杂志, 2023, 51(6): 572-618. DOI: 10.3760/cma.j.cn112148-20230416-00221. [5] DE ALMEIDA J P H C L, MARTINHO A S, GIRA~O A, et al. Novel anticoagulants in an older and frail population with atrial fibrillation: the effect of inappropriate dosing on clinical outcomes[J]. Eur Geriatr Med, 2020, 11(5): 813-820. DOI: 10.1007/s41999-020-00343-w. [6] 梁海军, 颜文华. 低剂量与标准剂量艾多沙班对老年非瓣膜性房颤患者抗凝治疗的效果研究[J]. 中国药物滥用防治杂志, 2021, 27(5): 689-691. DOI: 10.15900/j.cnki.zylf1995.2021.05.017. [7] PERREAULT S, CÔTÉ R, DRAGOMIR A, et al. Effectiveness and safety of low-dose versus standard-dose rivaroxaban and apixaban in patients with atrial fibrillation[J]. PLoS One, 2022, 17(12): e0277744. DOI: 10.1371/journal.pone.0277744. [8] TAOUTEL R, EZEKOWITZ M D, CHAUDHRY U A, et al. Retrospective comparison of patients≥80 years with atrial fibrillation prescribed either an FDA-approved reduced or full dose direct-acting oral anticoagulant[J]. Int J Cardiol Heart Vasc, 2022, 43: 101130. DOI: 10.1016/j.ijcha.2022.101130. [9] 王倩, 张丽, 黄俊, 等. 利伐沙班在高龄非瓣膜性心房颤动患者中的常用剂量及预后分析[J]. 岭南心血管病杂志, 2019, 25(6): 638-641, 646. DOI: 10.3969/j.issn.1007-9688.2019.06.10. [10] 温斌. 低剂量利伐沙班对高龄非瓣膜性房颤患者的抗栓疗效及安全性研究[D]. 南昌: 南昌大学, 2022: 1-47. [11] 张思婷. 80岁以上老年人应用利伐沙班的疗效及安全性分析[D]. 广州: 广州医科大学, 2021:1-55. [12] 张婧, 曹钰琨, 李妍妍, 等. 超高龄非瓣膜性房颤患者使用利伐沙班抗凝治疗的单中心经验[J]. 中华老年多器官疾病杂志, 2023, 22(3): 181-185. DOI: 10.11915/j.issn.1671-5403.2023.03.037. [13] PATEL M R, MAHAFFEY K W, GARG J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation[J]. N Engl J Med, 2011, 365(10): 883-891. DOI: 10.1056/NEJMoa1009638. [14] GRANGER C B, ALEXANDER J H, MCMURRAY J J V, et al. Apixaban versus warfarin in patients with atrial fibrillation[J]. N Engl J Med, 2011, 365(11): 981-992. DOI: 10.1056/NEJMoa1107039. [15] GIUGLIANO R P, RUFF C T, BRAUNWALD E, et al. Edoxaban versus warfarin in patients with atrial fibrillation[J]. N Engl J Med, 2013, 369(22): 2093-2104. DOI: 10.1056/NEJMoa1310907. [16] CONNOLLY S J, EZEKOWITZ M D, YUSUF S, et al. Dabigatran versus warfarin in patients with atrial fibrillation[J]. N Engl J Med, 2009, 361(12): 1139-1151. DOI: 10.1056/NEJMoa0905561. [17] LEE S R, LEE Y S, PARK J S, et al. Label adherence for non-vitamin K antagonist oral anticoagulants in a prospective cohort of Asian patients with atrial fibrillation[J]. Yonsei Med J, 2019, 60(3): 277-284. DOI: 10.3349/ymj.2019.60.3.277. [18] AGGARWAL V, ARMSTRONG E J, LIU W H, et al. Prasugrel use following PCI and associated patient outcomes: insights from the national VA CART program[J]. Clin Cardiol, 2016, 39(10): 578-584. DOI: 10.1002/clc.22568. [19] LIANG F, WANG Y. Coronary heart disease and atrial fibrillation: a vicious cycle[J]. Am J Physiol Heart Circ Physiol, 2021, 320(1): H1-H12. DOI: 10.1152/ajpheart.00702.2020. [20] YAO X X, SHAH N D, SANGARALINGHAM L R, et al. Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction[J]. J Am Coll Cardiol, 2017, 69(23): 2779-2790. DOI: 10.1016/j.jacc.2017.03.600. [21] CARBONE A, SANTELLI F, BOTTINO R, et al. Prevalence and clinical predictors of inappropriate direct oral anticoagulant dosage in octagenarians with atrial fibrillation[J]. Eur J Clin Pharmacol, 2022, 78(5): 879-886. DOI: 10.1007/s00228-022-03286-2. [22] OKUMURA K, AKAO M, YOSHIDA T, et al. Low-dose edoxaban in very elderly patients with atrial fibrillation[J]. N Engl J Med, 2020, 383(18): 1735-1745. DOI: 10.1056/NEJMoa2012883. [23] AURSULESEI V, COSTACHE I I. Anticoagulation in chronic kidney disease: from guidelines to clinical practice[J]. Clin Cardiol, 2019, 42(8): 774-782. DOI: 10.1002/clc.23196. |